Supernus Pharmaceuticals to Participate in September Investor Conferences
Supernus Pharmaceuticals plans September 2026 investor conference appearances with fireside chats and online webcast access for interested investors.
Rhea-AI Summary
Supernus Pharmaceuticals (SUPN) will participate in two September 2026 investor conferences, featuring management fireside chats in New York and Boston-area venues.
The company is scheduled for the Cantor Global Healthcare Conference on September 9, 2026 at 2:45 p.m. ET at the Waldorf Astoria in New York, and the Wells Fargo Healthcare Conference on September 10, 2026 at 12:45 p.m. ET at Encore Boston Harbor in Everett, Massachusetts. Investors are directed to contact conference coordinators to arrange meetings. A live audio webcast of the Jefferies Global Healthcare Conference and 60‑day archived replays will be accessible via the Events & Presentations section of the company’s website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 31 | Partnership announcement | Positive | +1.1% | Chloe Kim ambassador partnership supported Qelbree awareness and adult ADHD treatment dialogue. |
| Aug 03 | 2Q26 earnings report | Positive | +3.1% | Second-quarter revenue growth, raised guidance, and merger disclosure accompanied the results release. |
| Aug 03 | Merger agreement | Positive | +3.1% | All-stock merger-of-equals agreement with Indivior outlined scale, synergies, and approval conditions. |
| Jul 22 | Results scheduling notice | Neutral | +0.5% | Company scheduled second-quarter results and a conference call for August 4. |
| Jul 14 | FDA anniversary item | Positive | -1.5% | Qelbree approval anniversary highlighted prescriptions, labeling updates, and safety warnings for patients. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive announcements generally coincided with positive reactions, while the July 14 FDA anniversary item diverged with a negative reaction.
Key Terms
cns medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following September investor conferences:
| Cantor Global Healthcare Conference | |
| Date: | Wednesday, September 9, 2026 |
| Fireside chat: | 2:45 p.m. ET |
| Place: | Waldorf Astoria, New York, NY |
| Webcast Link: | Here |
| Wells Fargo Healthcare Conference | |
| Date: | Thursday, September 10, 2026 |
| Fireside chat: | 12:45 p.m. ET |
| Place: | Encore Boston Harbor, Everett, Mass. |
| Webcast Link: | Here |
Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators.
A live audio webcast of the Jefferies Global Healthcare Conference can also be accessed on the Events & Presentations section of the Supernus Pharmaceuticals website at www.supernus.com. Archived replays of the webcast will be available for 60 days on the Company's website following the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products, and the products of its subsidiaries; the Company's ability to increase its net revenue from its products, and the products of its subsidiaries; the Company's ability to commercialize its products, and the products of its subsidiaries; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
FAQ
When will Supernus Pharmaceuticals (SUPN) present at the Cantor Global Healthcare Conference in September 2026?
Supernus Pharmaceuticals is scheduled to participate in a fireside chat at the Cantor Global Healthcare Conference on
What is the schedule for Supernus Pharmaceuticals (SUPN) at the Wells Fargo Healthcare Conference in September 2026?
Supernus Pharmaceuticals is set to appear at the Wells Fargo Healthcare Conference on Thursday, September 10, 2026, with a fireside chat scheduled for 12:45 p.m. ET at Encore Boston Harbor in Everett, Massachusetts.
How can investors listen to Supernus Pharmaceuticals’ September 2026 conference webcasts for SUPN?
A live audio webcast of the Jefferies Global Healthcare Conference featuring Supernus can be accessed through the Events & Presentations section of the company’s website. Archived replays of the webcast will be available on the site for 60 days.
How can investors arrange meetings with Supernus Pharmaceuticals (SUPN) management at the September 2026 conferences?
Investors interested in scheduling a meeting with Supernus Pharmaceuticals’ management during the September investor conferences are advised to contact the respective conference coordinators directly.